Bausch & Lomb Incorporated – FDA 483, May 26, 2017
The FDA inspection of Bausch & Lomb, Inc. in Tampa, FL, revealed significant deficiencies across multiple systems, including production, facilities, quality, and laboratory controls. Key issues included the release of drug products potentially contaminated with Burkholderia cepacia, inadequate aseptic processing controls, and failures in complaint handling and investigations. These findings indicate a systemic lack of adherence to cGMP requirements, posing potential risks to drug product quality and patient safety.
ID · 96b666d6-5ab2-48f9-aae2-b0bf75cb29f0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.